These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 1777585)

  • 1. Cardiovascular complications in renal failure.
    Rostand SG; Brunzell JD; Cannon RO; Victor RG
    J Am Soc Nephrol; 1991 Dec; 2(6):1053-62. PubMed ID: 1777585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis.
    de Lemos JA; Hillis LD
    J Am Soc Nephrol; 1996 Oct; 7(10):2044-54. PubMed ID: 8915964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic value of myocardial thallium stress scintigraphy in the detection of coronary artery disease in patients undergoing chronic hemodialysis].
    Dahan M; Legallicier B; Himbert D; Faraggi M; Aubry N; Siohan P; Viron B; Gourgon R; Mignon F
    Arch Mal Coeur Vaiss; 1995 Aug; 88(8):1121-3. PubMed ID: 8572857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac consequences of hypertension in hemodialysis patients.
    Zoccali C; Benedetto FA; Tripepi G; Mallamaci F
    Semin Dial; 2004; 17(4):299-303. PubMed ID: 15250922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular disease in patients with end-stage renal disease on hemodialysis in a developing country.
    Silva LS; Oliveira RA; Silva GB; Lima JW; Silva RP; Liborio AB; Daher EF; Sobrinho CR
    Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):262-6. PubMed ID: 22382216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid abnormalities in chronic renal failure, nephrotic syndrome and dialysis.
    Kes P
    Acta Med Croatica; 2001; 55(4-5):177-86. PubMed ID: 12398021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of dyslipidemia in end-stage renal disease.
    Prichard SS
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S315-20. PubMed ID: 12939388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hypertension in renal failure patients: when do we overtreat? When do we undertreat?
    Rosansky SJ
    Blood Purif; 1996; 14(4):315-20. PubMed ID: 8873957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
    Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
    Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of subclinical left ventricular dysfunction in ESRD.
    Fathi R; Isbel N; Haluska B; Case C; Johnson DW; Marwick TH
    Am J Kidney Dis; 2003 May; 41(5):1016-25. PubMed ID: 12722036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
    Kes P; Reiner Z; Brunetta B
    Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?
    Raggi P; Boulay A; Chasan-Taber S; Amin N; Dillon M; Burke SK; Chertow GM
    J Am Coll Cardiol; 2002 Feb; 39(4):695-701. PubMed ID: 11849871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atherogenic lipoproteins in end-stage renal disease.
    Shoji T; Ishimura E; Inaba M; Tabata T; Nishizawa Y
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S30-3. PubMed ID: 11576918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of ventricular fibrillation, acute myocardial infarction (myocardial necrosis), heart failure, and mortality by bretylium: is ischemic heart disease primarily adrenergic cardiovascular disease?
    Bacaner M; Brietenbucher J; LaBree J
    Am J Ther; 2004; 11(5):366-411. PubMed ID: 15356432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dipyridamole-echocardiography and thallium exercise myocardial scintigraphy in the diagnosis of obstructive coronary or microvascular disease in hypertensive patients with left ventricular hypertrophy and angina].
    Astarita C; Nicolai E; Liguori E; Gambardella S; Rumolo S; Maresca FS
    G Ital Cardiol; 1998 Sep; 28(9):996-1004. PubMed ID: 9788038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.
    Quaschning T; Krane V; Metzger T; Wanner C
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S14-9. PubMed ID: 11576915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular mortality in end-stage renal disease.
    Collins AJ
    Am J Med Sci; 2003 Apr; 325(4):163-7. PubMed ID: 12695721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Left ventricular hypertrophy and myocardial ischemia (coronary atherosclerosis excluded)].
    Bounhoure JP; Galinier M
    Arch Mal Coeur Vaiss; 1991 Sep; 84 Spec No 3():107-10. PubMed ID: 1835363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.